The company said that for the 3 months ended March 31, 2024, revenue was $5,045 million ($4,821 million a year earlier, up 4.6%), GAAP diluted EPS was $1.85, and adjusted diluted EPS was $3.17 (up 10.8%).

1. 01

   The company said that for the 3 months ended March 31, 2024, revenue was $5,045 million ($4,821 million a year earlier, up 4.6%), GAAP diluted EPS was $1.85, and adjusted diluted EPS was $3.17 (up 10.8%).

2. 02

   BD said that for the 3 months, BD Medical revenue was $2,449 million (up 3.8%), BD Life Sciences revenue was $1,304 million (2.2%), and BD Interventional revenue was $1,292 million (9.0%, organic 13.6%).

3. 03

   The company reported that for the 6 months, cash from continuing operations was $1,369 million ($584 million a year earlier), and free cash flow, after subtracting capital expenditures of $250 million, was $1,119 million ($195 million a year earlier).

4. 04

   The company said its adjusted diluted EPS outlook for fiscal 2024 is $12.82 to $13.06, compared with $12.95 to $13.15 previously, and that its total revenue outlook is ~$20.1 billion to $20.3 billion (prior: ~$20.2 billion to $20.4 billion).

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.